$626 Million is the total value of Cormorant Asset Management, LP's 87 reported holdings in Q3 2015. The portfolio turnover from Q2 2015 to Q3 2015 was 16.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HRTX | Buy | HERON THERAPEUTICS INC | $41,132,000 | -8.3% | 1,685,719 | +17.1% | 6.57% | +10.1% |
| ALKS | ALKERMES PLC | $41,069,000 | -8.8% | 700,000 | 0.0% | 6.56% | +9.6% | |
| NBIX | NEUROCRINE BIOSCIENCES INC | $28,605,000 | -16.7% | 718,900 | 0.0% | 4.57% | +0.1% | |
| DYAX | DYAX CORP | $26,726,000 | -28.0% | 1,400,000 | 0.0% | 4.27% | -13.5% | |
| ARDX | ARDELYX INC | $25,593,000 | +8.2% | 1,481,075 | 0.0% | 4.09% | +30.0% | |
| ALDR | ALDER BIOPHARMACEUTICALS INC | $24,815,000 | -38.2% | 757,475 | 0.0% | 3.96% | -25.7% | |
| EGRX | EAGLE PHARMACEUTICALS INC | $22,209,000 | -8.4% | 300,000 | 0.0% | 3.55% | +10.0% | |
| OMER | Buy | OMEROS CORP | $21,482,000 | +207.4% | 1,960,000 | +404.5% | 3.43% | +269.3% |
| PTLA | PORTOLA PHARMACEUTICALS INC | $21,310,000 | -6.4% | 500,000 | 0.0% | 3.40% | +12.4% | |
| SRNE | Buy | SORRENTO THERAPEUTICS INC | $17,580,000 | -48.7% | 2,095,334 | +7.7% | 2.81% | -38.4% |
| QTNT | QUOTIENT LTD | $14,548,000 | -12.1% | 1,119,100 | 0.0% | 2.32% | +5.6% | |
| DVAX | Buy | DYNAVAX TECHNOLOGIES CORP | $14,111,000 | +20.5% | 575,000 | +15.0% | 2.25% | +44.8% |
| DXCM | DEXCOM INC | $13,137,000 | +7.4% | 153,000 | 0.0% | 2.10% | +28.9% | |
| NVRO | Buy | NEVRO CORP | $12,311,000 | +9.9% | 265,386 | +27.3% | 1.97% | +31.9% |
| BCRX | Buy | BIOCRYST PHARMACEUTICALS | $12,312,000 | +21.3% | 1,080,000 | +58.8% | 1.97% | +45.6% |
| TSRO | TESARO INC | $11,679,000 | -31.8% | 291,250 | 0.0% | 1.86% | -18.1% | |
| CHRS | COHERUS BIOSCIENCES INC | $11,405,000 | -30.7% | 569,130 | 0.0% | 1.82% | -16.7% | |
| NVAX | NOVAVAX INC | $11,312,000 | -36.5% | 1,600,000 | 0.0% | 1.81% | -23.8% | |
| ALNY | ALNYLAM PHARMACEUTICALS INC | $11,250,000 | -33.0% | 140,000 | 0.0% | 1.80% | -19.5% | |
| RARE | Buy | ULTRAGENYX PHARMACEUTICAL IN | $10,546,000 | +1.0% | 109,500 | +7.4% | 1.68% | +21.2% |
| SAGE | New | SAGE THERAPEUTICS INC | $10,157,000 | – | 240,000 | +100.0% | 1.62% | – |
| CBPO | CHINA BIOLOGIC PRODS INC | $10,015,000 | -22.0% | 111,500 | 0.0% | 1.60% | -6.3% | |
| COLL | COLLEGIUM PHARMACEUTICAL INC | $9,950,000 | +23.9% | 450,000 | 0.0% | 1.59% | +48.9% | |
| REPH | RECRO PHARMA INC | $9,383,000 | -6.9% | 780,000 | 0.0% | 1.50% | +11.9% | |
| PFNX | PFENEX INC | $9,380,000 | -22.6% | 624,900 | 0.0% | 1.50% | -7.1% | |
| MRTX | New | MIRATI THERAPEUTICS INC | $8,777,000 | – | 255,000 | +100.0% | 1.40% | – |
| RMTI | Buy | ROCKWELL MED INC | $8,520,000 | +55.4% | 1,105,000 | +225.0% | 1.36% | +86.7% |
| ADXS | ADVAXIS INC | $8,184,000 | -49.7% | 800,000 | 0.0% | 1.31% | -39.5% | |
| FWP | Buy | FORWARD PHARMA A/Ssponsored adr | $7,894,000 | -18.6% | 335,068 | +31.4% | 1.26% | -2.2% |
| LPCN | LIPOCINE INC NEW | $7,887,000 | +37.9% | 666,666 | 0.0% | 1.26% | +65.8% | |
| MCRB | Buy | SERES THERAPEUTICS INC | $7,410,000 | +257.1% | 250,000 | +400.0% | 1.18% | +329.0% |
| AGEN | AGENUS INC | $7,171,000 | -46.7% | 1,559,000 | 0.0% | 1.14% | -36.0% | |
| NERV | Sell | MINERVA NEUROSCIENCES INC | $6,011,000 | -9.5% | 1,145,043 | -0.0% | 0.96% | +8.7% |
| RGLS | REGULUS THERAPEUTICS INC | $5,863,000 | -40.3% | 896,522 | 0.0% | 0.94% | -28.3% | |
| CRIS | CURIS INC | $5,317,000 | -39.0% | 2,632,000 | 0.0% | 0.85% | -26.7% | |
| ZYNE | New | ZYNERBA PHARMACEUTICALS INC | $5,103,000 | – | 356,600 | +100.0% | 0.82% | – |
| XLRN | ACCELERON PHARMA INC | $4,980,000 | -21.3% | 200,000 | 0.0% | 0.80% | -5.5% | |
| APTOSE BIOSCIENCES INC | $4,713,000 | -15.0% | 1,081,867 | 0.0% | 0.75% | +2.2% | ||
| ATRA | Buy | ATARA BIOTHERAPEUTICS INC | $4,716,000 | +78.8% | 150,000 | +200.0% | 0.75% | +114.5% |
| New | INTEC PHARMA LTD JERUSALEM | $4,480,000 | – | 800,000 | +100.0% | 0.72% | – | |
| NKTR | NEKTAR THERAPEUTICS | $4,357,000 | -12.4% | 397,500 | 0.0% | 0.70% | +5.3% | |
| DERM | DERMIRA INC | $3,968,000 | +33.0% | 170,000 | 0.0% | 0.63% | +59.7% | |
| EPRSQ | EPIRUS BIOPHARMACEUTICALS INC | $3,963,000 | -22.6% | 896,600 | 0.0% | 0.63% | -7.0% | |
| ARRY | ARRAY BIOPHARMA INC | $3,876,000 | -36.8% | 850,000 | 0.0% | 0.62% | -24.0% | |
| KITE | KITE PHARMA INC | $3,831,000 | -8.7% | 68,800 | 0.0% | 0.61% | +9.7% | |
| RGNX | New | REGENXBIO INC | $3,453,000 | – | 156,741 | +100.0% | 0.55% | – |
| EPZM | EPIZYME INC | $3,424,000 | -46.4% | 266,250 | 0.0% | 0.55% | -35.6% | |
| KPTI | KARYOPHARM THERAPEUTICS INC | $3,169,000 | -61.3% | 300,987 | 0.0% | 0.51% | -53.5% | |
| CYAD | CELYAD SAadr | $3,139,000 | -19.6% | 75,000 | 0.0% | 0.50% | -3.5% | |
| LBIO | LION BIOTECHNOLOGIES INC | $2,879,000 | -37.2% | 499,815 | 0.0% | 0.46% | -24.5% | |
| GNVC | GENVEC INC | $2,717,000 | +13.2% | 1,176,235 | 0.0% | 0.43% | +36.1% | |
| TETRALOGIC PHARMACEUTICALS Cnote 8.000% 6/1 | $2,647,000 | -11.1% | 5,000,000 | 0.0% | 0.42% | +6.8% | ||
| ACRX | ACELRX PHARMACEUTICALS INC | $2,593,000 | -28.1% | 850,000 | 0.0% | 0.41% | -13.6% | |
| GLYC | GLYCOMIMETICS INC | $2,570,000 | -29.6% | 458,955 | 0.0% | 0.41% | -15.5% | |
| IMDZ | IMMUNE DESIGN CORP | $2,306,000 | -40.9% | 189,000 | 0.0% | 0.37% | -29.1% | |
| OVAS | OVASCIENCE INC | $2,141,000 | -70.7% | 252,180 | 0.0% | 0.34% | -64.7% | |
| BPMC | BLUEPRINT MEDICINES CORP | $2,134,000 | -19.4% | 100,000 | 0.0% | 0.34% | -3.1% | |
| AQXP | Sell | AQUINOX PHARMACEUTICALS INC | $2,111,000 | +8.6% | 150,000 | -46.4% | 0.34% | +30.6% |
| FOLD | Sell | AMICUS THERAPEUTICS INC | $2,099,000 | -25.8% | 150,000 | -25.0% | 0.34% | -10.9% |
| SGMO | SANGAMO BIOSCIENCES INC | $2,036,000 | -49.1% | 361,000 | 0.0% | 0.32% | -38.9% | |
| CERU | CERULEAN PHARMA INC | $2,018,000 | -20.4% | 551,354 | 0.0% | 0.32% | -4.5% | |
| DRNA | DICERNA PHARMACEUTICALS INC | $2,011,000 | -41.2% | 245,000 | 0.0% | 0.32% | -29.3% | |
| VSAR | VERSARTIS INC | $1,960,000 | -24.2% | 170,000 | 0.0% | 0.31% | -9.0% | |
| AVEO | AVEO PHARMACEUTICALS INC | $1,921,000 | -30.5% | 1,587,715 | 0.0% | 0.31% | -16.3% | |
| KIN | KINDRED BIOSCIENCES INC | $1,708,000 | -23.8% | 328,497 | 0.0% | 0.27% | -8.4% | |
| QTNTW | New | QUOTIENT LTD*w exp 10/30/201 | $1,630,000 | – | 500,000 | +100.0% | 0.26% | – |
| HTGM | HTG MOLECULAR DIAGNOSTICS IN | $1,532,000 | -31.6% | 201,000 | 0.0% | 0.24% | -17.8% | |
| PVCT | PROVECTUS BIOPHARMACEUTICALS | $1,265,000 | +6.5% | 2,200,000 | 0.0% | 0.20% | +27.8% | |
| AGRX | AGILE THERAPEUTICS INC | $1,227,000 | -21.5% | 182,053 | 0.0% | 0.20% | -5.8% | |
| ASND | ASCENDIS PHARMA A Ssponsored adr | $1,089,000 | +0.2% | 61,500 | 0.0% | 0.17% | +20.0% | |
| DNAI | New | PRONAI THERAPEUTICS INC | $1,091,000 | – | 53,153 | +100.0% | 0.17% | – |
| NEOS | New | NEOS THERAPEUTICS INC | $1,051,000 | – | 50,000 | +100.0% | 0.17% | – |
| CFRX | CONTRAFECT CORP | $1,043,000 | -15.3% | 234,406 | 0.0% | 0.17% | +1.8% | |
| CLRB | CELLECTAR BIOSCIENCES INC | $1,044,000 | -31.6% | 530,000 | 0.0% | 0.17% | -17.7% | |
| AKBA | AKEBIA THERAPEUTICS INC | $969,000 | -6.1% | 100,300 | 0.0% | 0.16% | +13.1% | |
| SCYX | SCYNEXIS INC | $723,000 | -17.2% | 99,366 | 0.0% | 0.12% | -0.9% | |
| PVCTW | PROVECTUS BIOPHARMACEUTICALS*w exp 06/24/202 | $686,000 | +42.9% | 2,200,000 | 0.0% | 0.11% | +71.9% | |
| AKTX | New | AKARI THERAPEUTICS PLCsponsored adr | $687,000 | – | 28,650 | +100.0% | 0.11% | – |
| GALT | GALECTIN THERAPEUTICS INC | $670,000 | -14.2% | 286,200 | 0.0% | 0.11% | +2.9% | |
| BITI | BIOTIE THERAPIES OYJsponsored adr | $655,000 | -34.4% | 50,000 | 0.0% | 0.10% | -21.1% | |
| VCYT | VERACYTE INC | $647,000 | -57.9% | 137,990 | 0.0% | 0.10% | -49.5% | |
| NSTG | Sell | NANOSTRING TECHNOLOGIES INC | $640,000 | -48.1% | 40,000 | -50.0% | 0.10% | -37.8% |
| CLRBW | CELLECTAR BIOSCIENCES INC*w exp 08/19/201 | $451,000 | +9.2% | 530,000 | 0.0% | 0.07% | +30.9% | |
| CLLS | CELLECTIS S Asponsored ads | $298,000 | -27.0% | 11,300 | 0.0% | 0.05% | -11.1% | |
| ADAP | ADAPTIMMUNE THERAPEUTICS PLCsponds adr | $299,000 | -34.7% | 25,000 | 0.0% | 0.05% | -21.3% | |
| AGTC | APPLIED GENETIC TECHNOL CORP | $225,000 | -14.1% | 17,110 | 0.0% | 0.04% | +2.9% | |
| New | HERON THERAPEUTICS INC | $100,000 | – | 5,000 | +100.0% | 0.02% | – | |
| CLTX | Exit | CELSUS THERAPEUTICS PLCsponsored adr ne | $0 | – | -286,508 | -100.0% | -0.02% | – |
| KERX | Exit | KERYX BIOPHARMACEUTICALS INC | $0 | – | -826,000 | -100.0% | -1.10% | – |
| RCPT | Exit | RECEPTOS INC | $0 | – | -220,000 | -100.0% | -5.56% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-11-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
| ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
| MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
| ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
| OMEROS CORP | 27 | Q3 2021 | 6.5% |
| MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
| BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
| APELLIS PHARMACEUTICALS INC | 24 | Q3 2023 | 8.6% |
| NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
| ROCKET PHARMACEUTICALS, INC | 23 | Q3 2023 | 2.4% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | March 13, 2023 | 42,771,365 | - |
| Altimmune, Inc. | February 14, 2023 | 2,600,000 | - |
| Arcellx, Inc. | February 14, 2023 | 2,075,000 | - |
| BioAtla, Inc. | February 14, 2023 | 2,499,250 | - |
| Eledon Pharmaceuticals, Inc. | February 14, 2023 | 1,391,663 | - |
| GreenLight Biosciences Holdings, PBC | February 14, 2023 | 4,751,020 | - |
| Prometheus Biosciences, Inc. | February 14, 2023 | 700,000 | - |
| Tango Therapeutics, Inc. | February 14, 2023 | 1,000,000 | - |
| VectivBio Holding AG | February 14, 2023 | 1,515,087 | - |
| Viridian Therapeutics, Inc.\DE | February 14, 2023 | 1,100,000 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-22 |
| SC 13G/A | 2024-04-15 |
| 4 | 2024-04-03 |
| SC 13G | 2024-03-21 |
| 4 | 2024-03-18 |
| SC 13G/A | 2024-03-18 |
| 4 | 2024-03-11 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.